Priveterra Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing April 1, 2021

Rhea-AI Summary

Priveterra Acquisition Corp. (Nasdaq: PMGMU) announced that, starting April 1, 2021, holders of units from its IPO can separately trade Class A common stock and warrants. The common stock will trade under the symbol 'PMGM' and warrants under 'PMGMW.' Only whole warrants will be issued, with no fractional warrants available. The company, aimed at acquiring a business in medical technology, listed Wells Fargo Securities and Guggenheim Securities as joint book-runners for the offering. This news does not constitute an offer to sell securities.

Positive

• Opportunity for unit holders to trade shares and warrants separately.
• Potential to attract more liquidity in the stock with separate trading.
• Strategic focus on the medical technology sector for future acquisitions.

Negative

• None.

FORT LAUDERDALE, Fla., March 25, 2021 (GLOBE NEWSWIRE) -- Priveterra Acquisition Corp. (Nasdaq: PMGMU) (the “Company”) today announced that, commencing April 1, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units.

No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The shares of Class A common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “PMGM” and “PMGMW,” respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol “PMGMU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants.

Priveterra Acquisition Corp. is a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to seek a target in medical technology.

Wells Fargo Securities and Guggenheim Securities acted as the joint book-runners for the offering. Odeon Capital Group acted as co-manager for the offering.

The offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or emailing a request to cmclientsupport@wellsfargo.com and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

A registration statement relating to these securities was declared effective by the SEC on February 8, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the search for an initial business combination. No assurance can be given that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

David Meredith
Chief Legal Officer and Secretary
Priveterra Acquisition Corp.
+1 (754)-220-9229
dm@priveterra.com

FAQ

What does Priveterra Acquisition Corp. (PMGMU) offer for unit holders?

Starting April 1, 2021, unit holders can trade shares of Class A common stock and warrants separately.

What are the trading symbols for Priveterra shares and warrants?

Class A common stock will trade under 'PMGM' and warrants under 'PMGMW'.

What is the purpose of Priveterra Acquisition Corp.?

The company is formed to effect a merger or similar business combination, specifically targeting the medical technology sector.

Who were the joint book-runners for the Priveterra IPO?

Wells Fargo Securities and Guggenheim Securities acted as joint book-runners for the offering.

When was the registration statement for Priveterra's securities declared effective?

The registration statement was declared effective by the SEC on February 8, 2021.